Cancer acute myeloid leukemia

Over 70% of transplantations were carried out concerning lympho-granulematosis, lymphoma, and myeloma others are connected with testicular cancer, acute myeloid leukemia, solid tumors and other oncological diseases. The lethality related with transplantation (100-days lethality among the transplanted patients) was 2,3% (died 4 patients) within 5 years. At the beginning of 2006 56% of all transplanted patients did not have the signs of basic disease progression. 

Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 2004 4 56. 

Gregory J, Arced R. Acute myeloid leukemia in children A review of risk factors and recent trials. Cancer Invest 2002 20 1027-1037. 

Cancers Multiple myeloma Non-Hodgkin s lymphoma Hodgkin s disease Acute myeloid leukemia Neuroblastoma Germ cell tumors Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Myelodysplastic syndrome Myeloproliferative disorders Non-Hodgkin s lymphoma Hodgkin s disease Chronic lymphocytic leukemia Multiple myeloma... 

Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., and Pazdur, R. (2001) Approval summary Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-1496. 

Carapeti M, Aguiar RC, Goldman JM, Cross NC (1998) A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91 3127—3133 Chaffanet M, Gressin L, Preudhomme C, Soenen-Comu V, Bimbaum D, Pebusque MJ (2000) MOZ is fused to p300 in an acute monocytic leukemia with t(8 22). Genes Chromosomes. Cancer 28 138—144... 

Rozman M, Camos M, Colomer D, Villamor N, Esteve J, Costa D, Carrio A, Aymerich M, Aguilar JL, Domingo A, Sole F, Gomis F, Florensa L, Montserrat E, Campo E (2004) Type I MOZICBP (MYST31CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8 16)(pll pl3) translocation. Genes Chromosomes. Cancer 40 140-145 Rubinstein JH, Taybi H (1963) Broad thumbs and toes and facial abnormalities. Am J Dis Child 105 588-608... 

Ulmer, T., Schuler, U.S., Thiede, C., et al. (2002) MDRl gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62, 4955-4962. 

Higuchi, M., O Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E.-J. and Downing, J. (2002) Expression of a conditional AMLl-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8 21) acute myeloid leukemia. Cancer Cell 1, 63-74. 

Kuo, Y., Landrette, S., Heilman, S., Perrat, P., Garrett, L., Liu, P., Beau, M.L., Kogan, S. and Castilla, L. (2006) Cbfp SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer CellQ, 57-68. 

Somervaille, T. and Cleary, M. (2006) Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257-268. 

Giles F, Estey E, O Brien S. (2003) Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 98 2095-2104. 

Mongelard F, Bouvet P (2010) AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther 1 107-114... 

Orsolie N, Golemovie M, Quintas-Cardama A et al. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci 2006 97 952-960. 

In June 1999, phase I clinical trials of OTI-010 were initiated in cancer patients receivingchemotherapy and HSC transplantation for the treatment of high-risk hematological malignancies (including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and non-Hodgkin s lymphoma). The multicenter studies, conducted in seven US and European cancer centers, showed OTI-010 to be safe and efficacious, with 52% of patients ( 40 patients) responding positively to the therapy [327297], [495015]. 

Currently, 17 mAbs have been approved in the United States (US) for therapeutic use in organ transplant, percutaneous coronary intervention, prophylaxis of respiratory syncytial virus, RA, Crohn s disease, asthma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, non-Hodgkin s lymphoma, breast cancer, and colorectal cancer. All approved mAbs are of the IgG class 13 human IgG1 one igG4, and two murine IgG2a. Thirteen are intact mAbs, three are conjugated, and one is a Fab fragment (Tables 12.2 to 12.4). 

---